vs
CBL & ASSOCIATES PROPERTIES INC（CBL）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是CBL & ASSOCIATES PROPERTIES INC的1.4倍（$219.9M vs $156.4M），CBL & ASSOCIATES PROPERTIES INC净利率更高（31.3% vs -1.0%，领先32.3%），CBL & ASSOCIATES PROPERTIES INC同比增速更快（18.8% vs 2.0%），过去两年CBL & ASSOCIATES PROPERTIES INC的营收复合增速更高（10.1% vs 8.0%）
CBL联合地产是一家美国房地产投资信托企业，核心投资布局为购物中心与商业摩尔，业务主要集中在美国东南部与中西部地区。公司在特拉华州注册，总部设于田纳西州查塔努加，该城市也是其最大的布局市场，公司名称取自创始人查尔斯·B·勒博维茨的姓名首字母。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CBL vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.4倍
$156.4M
营收增速更快
CBL
高出16.8%
2.0%
净利率更高
CBL
高出32.3%
-1.0%
两年增速更快
CBL
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $219.9M |
| 净利润 | $49.0M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 31.3% | -1.0% |
| 营收同比 | 18.8% | 2.0% |
| 净利润同比 | 29.0% | 92.4% |
| 每股收益（稀释后） | $1.61 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBLOFIX
| Q4 25 | $156.4M | $219.9M | ||
| Q3 25 | $139.3M | $205.6M | ||
| Q2 25 | $140.9M | $203.1M | ||
| Q1 25 | $141.8M | $193.6M | ||
| Q4 24 | $131.7M | $215.7M | ||
| Q3 24 | $125.1M | $196.6M | ||
| Q2 24 | $129.7M | $198.6M | ||
| Q1 24 | $129.1M | $188.6M |
净利润CBLOFIX
| Q4 25 | $49.0M | $-2.2M | ||
| Q3 25 | $75.4M | $-22.8M | ||
| Q2 25 | $2.8M | $-14.1M | ||
| Q1 25 | $8.8M | $-53.1M | ||
| Q4 24 | $38.0M | $-29.1M | ||
| Q3 24 | $16.2M | $-27.4M | ||
| Q2 24 | $4.7M | $-33.4M | ||
| Q1 24 | $50.0K | $-36.0M |
毛利率CBLOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率CBLOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | — | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率CBLOFIX
| Q4 25 | 31.3% | -1.0% | ||
| Q3 25 | 54.2% | -11.1% | ||
| Q2 25 | 2.0% | -6.9% | ||
| Q1 25 | 6.2% | -27.4% | ||
| Q4 24 | 28.8% | -13.5% | ||
| Q3 24 | 12.9% | -13.9% | ||
| Q2 24 | 3.7% | -16.8% | ||
| Q1 24 | 0.0% | -19.1% |
每股收益（稀释后）CBLOFIX
| Q4 25 | $1.61 | $-0.05 | ||
| Q3 25 | $2.38 | $-0.57 | ||
| Q2 25 | $0.08 | $-0.36 | ||
| Q1 25 | $0.27 | $-1.35 | ||
| Q4 24 | $1.22 | $-0.76 | ||
| Q3 24 | $0.52 | $-0.71 | ||
| Q2 24 | $0.14 | $-0.88 | ||
| Q1 24 | $-0.01 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $42.3M | $82.0M |
| 总债务越低越好 | $2.2B | — |
| 股东权益账面价值 | $374.9M | $450.0M |
| 总资产 | $2.7B | $850.6M |
| 负债/权益比越低杠杆越低 | 5.79× | — |
8季度趋势，按日历期对齐
现金及短期投资CBLOFIX
| Q4 25 | $42.3M | $82.0M | ||
| Q3 25 | $52.6M | $62.9M | ||
| Q2 25 | $100.3M | $65.6M | ||
| Q1 25 | $100.3M | $58.0M | ||
| Q4 24 | $40.8M | $83.2M | ||
| Q3 24 | $65.1M | $30.1M | ||
| Q2 24 | $57.7M | $26.4M | ||
| Q1 24 | $57.7M | $27.0M |
总债务CBLOFIX
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $157.2M | ||
| Q2 25 | $2.1B | $157.0M | ||
| Q1 25 | $2.2B | $156.9M | ||
| Q4 24 | $2.2B | $157.0M | ||
| Q3 24 | $1.8B | $118.5M | ||
| Q2 24 | $1.9B | $118.0M | ||
| Q1 24 | $1.9B | $118.2M |
股东权益CBLOFIX
| Q4 25 | $374.9M | $450.0M | ||
| Q3 25 | $351.4M | $442.5M | ||
| Q2 25 | $289.4M | $458.3M | ||
| Q1 25 | $295.0M | $458.3M | ||
| Q4 24 | $323.5M | $503.1M | ||
| Q3 24 | $308.3M | $525.9M | ||
| Q2 24 | $308.8M | $546.0M | ||
| Q1 24 | $324.2M | $570.3M |
总资产CBLOFIX
| Q4 25 | $2.7B | $850.6M | ||
| Q3 25 | $2.7B | $832.6M | ||
| Q2 25 | $2.6B | $837.2M | ||
| Q1 25 | $2.6B | $823.1M | ||
| Q4 24 | $2.7B | $893.3M | ||
| Q3 24 | $2.2B | $867.9M | ||
| Q2 24 | $2.3B | $882.0M | ||
| Q1 24 | $2.3B | $906.0M |
负债/权益比CBLOFIX
| Q4 25 | 5.79× | — | ||
| Q3 25 | 6.21× | 0.36× | ||
| Q2 25 | 7.39× | 0.34× | ||
| Q1 25 | 7.29× | 0.34× | ||
| Q4 24 | 6.84× | 0.31× | ||
| Q3 24 | 5.76× | 0.23× | ||
| Q2 24 | 6.00× | 0.22× | ||
| Q1 24 | 5.74× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $249.7M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | 5.10× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CBLOFIX
| Q4 25 | $249.7M | $27.7M | ||
| Q3 25 | $69.6M | $12.4M | ||
| Q2 25 | $68.3M | $11.6M | ||
| Q1 25 | $31.7M | $-18.4M | ||
| Q4 24 | $202.2M | $23.7M | ||
| Q3 24 | $61.1M | $11.7M | ||
| Q2 24 | $64.2M | $9.0M | ||
| Q1 24 | $30.7M | $-18.6M |
自由现金流CBLOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | $46.0M | $6.3M | ||
| Q2 24 | $54.8M | $-360.0K | ||
| Q1 24 | $24.7M | $-29.1M |
自由现金流率CBLOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | 36.8% | 3.2% | ||
| Q2 24 | 42.2% | -0.2% | ||
| Q1 24 | 19.1% | -15.4% |
资本支出强度CBLOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | 12.1% | 2.7% | ||
| Q2 24 | 7.3% | 4.7% | ||
| Q1 24 | 4.7% | 5.6% |
现金转化率CBLOFIX
| Q4 25 | 5.10× | — | ||
| Q3 25 | 0.92× | — | ||
| Q2 25 | 24.74× | — | ||
| Q1 25 | 3.60× | — | ||
| Q4 24 | 5.32× | — | ||
| Q3 24 | 3.77× | — | ||
| Q2 24 | 13.54× | — | ||
| Q1 24 | 614.76× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBL
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
